Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature Medicine 11, 379 - 380 (2005)
doi:10.1038/nm0405-379
Beyond beta blockers
Donald M Bers1
- The author is in the Department of Physiology, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois 60153, USA. e-mail: dbers@lumc.edu
Abstract
Blocking 
-adrenergic receptors is a standard treatment for heart failure, but it limits the normal ability to modulate cardiac function. Targeting therapy further downstream by blocking activation of calcium-calmodulin–dependent protein kinase could provide an alternative (pages 409–407).
In this issue, Zhang et al.1 investigate a new approach to treat heart failure—inhibition of calcium-calmodulin–dependent protein kinase II (CaMKII). This represents a potentially more specific target than the current standard therapy for heart failure, -adrenergic receptor blockade.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Sealing the leak, healing the heartNature Medicine News and Views (01 Aug 2003)
Locating heart failureNature Medicine News and Views (01 Dec 2005)
See all 6 matches for News And ViewsRESEARCH
Modulation of glomerular hypertension defines susceptibility to progressive glomerular injuryKidney International Original Article
Calmodulin kinase II inhibition protects against structural heart diseaseNature Medicine Article (01 Apr 2005)
See all 17 matches for Research